← All indications
Hemangiosarcoma
A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)
Drugs by status
Phase 4 trials (1)
Phase 2 trials (35)
- dexrazoxane
- agen1884
- talazoparib
- irinotecan
- selinexor
- doxorubicin
- eribulin
- ganitumab
- gemcitabine
- paclitaxel
- nivolumab
- pembrolizumab
- msk-2206
- olaratumab
- patritumab
- pazopanib
- pexidartinib
- trastuzumab
- ifosfamide
- propranolol
- ipilimumab
- pertuzumab
- sitagliptin
- ganetespib
- bevacizumab
- trastuzumab emtansine
- veliparib
- agen2034
- masct:multiple antigens specific cellular therapy
- docetaxel
- +5 more
Phase 1 trials (6)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (42)
- Eisai
- Amgen
- Merck
- Genentech
- Merck KGaA
- Pfizer
- Bayer
- GlaxoSmithKline
- Agenus Inc.
- Medical University of Graz
- Cancer Research UK
- Cornell University
- Harvard University
- Dong-A University
- Temple University
- Gottfried Wilhelm Leibniz Universität Hannover
- Medical University Innsbruck
- Northwestern University
- Oregon Health and Science University
- Southwest Oncology Group
- Stanford University
- Sheffield Hallam University
- University of Hamburg
- University of Heidelberg
- UNICANCER
- University of South Florida
- University of Birmingham
- Wake Forest University
- University of Witten/Herdecke
- QuantumLeap Healthcare Collaborative
- +12 more
Organization Involved with Phase 1 Indications (2)